Literature DB >> 3527524

The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy.

A Samanta, A C Burden, G R Jones, L Clarkson.   

Abstract

To determine the effect of short term intensive insulin therapy in non-insulin-dependent diabetes mellitus (NIDDM) we studied 10 patients who had been on maximal doses of sulphonylurea therapy, with a glycosylated haemoglobin value persistently above the normal range. All patients were non-ketonuric, had negative islet cell antibodies, and had been on sulphonylureas for a mean duration of 5.6 yr. Patients were maintained at euglycaemia (plasma glucose 4-7 mmol/l) for 24 hr using an open-loop intravenous insulin regimen, and then underwent a standard 75 g oral glucose tolerance test (OGTT). This was repeated after 3 months of treatment with insulin. Mean fasting plasma glucose and glycosylated haemoglobin were 10.1 mmol/l and 12.2% respectively before, and 7.1 mmol/l (p less than 0.001) and 8.4% (p less than 0.001) after treatment. There was no significant change in body weight. Plasma insulin and C-peptide responses to 75 g OGTT did not change significantly, but the total amount of intravenously infused insulin required for 24-hr euglycaemia fell from a mean value of 138 u before treatment to 87 u (p less than 0.001) at the end of insulin therapy. Remission, with glycosylated haemoglobin in the normal range for more than 3 months after stopping insulin, was observed in 5 out of the 10 patients. All 5 who failed to achieve remission had markedly blunted maximal insulin responses of less than 10 mu/l on both OGTT's. Our study shows that insulin treatment in NIDDM appears to exercise a beneficial effect by lowering insulin resistance. We suggest that this may be of advantage early on in patients with NIDDM in preserving B-cell reserve.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527524

Source DB:  PubMed          Journal:  Diabetes Res        ISSN: 0265-5985


  7 in total

1.  Effects of intensive insulin therapy upon pancreatic β cell function in patients newly diagnosed with type II diabetes.

Authors:  Defeng Wang; Li Sun; Guangyao Song; Shuchun Chen
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Authors:  Petra B Musholt; Thomas Schöndorf; Andreas Pfützner; Cloth Hohberg; Iris Kleine; Winfried Fuchs; Silvia Hehenwarter; Gerhard Dikta; Benedikt Kerschgens; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

3.  Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.

Authors:  Georg Biesenbach; Peter Grafinger; Andreas Raml
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

4.  The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients.

Authors:  Suk Chon; Seungjoon Oh; Sung Woon Kim; Jin-Woo Kim; Young Seol Kim; Jeong-taek Woo
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165

Review 5.  Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review.

Authors:  A Ilarde; M Tuck
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

6.  Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission.

Authors:  Yun Hu; Lirong Li; Yu Xu; Tingting Yu; Guoyu Tong; Hong Huang; Yan Bi; Jianping Weng; Dalong Zhu
Journal:  Diabetes Care       Date:  2011-06-16       Impact factor: 19.112

7.  Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.

Authors:  Harn-Shen Chen; Tzu-En Wu; Tjin-Shing Jap; Li-Chuan Hsiao; Shen-Hung Lee; Hong-Da Lin
Journal:  Diabetes Care       Date:  2008-06-12       Impact factor: 17.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.